GlassScriptPhysician profile
Mary E Lewis
NPI 1568861482
$3,783.45
in general payments reported to CMS, 2019-2025
30 companies · $1,441 in 2025
The $1,441 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $491 · 2022: $611 · 2023: $809 · 2024: $431 · 2025: $1,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,616 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,615.94 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $627.27 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $558.95 | 2021-2025 | Fasenra, Tezspire, Farxiga |
| Harmony Biosciences LLC | $487.89 | 2025 | |
| Lilly USA, LLC | $337.27 | 2021-2024 | Mounjaro, Trulicity, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.67 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $283.01 | 2021-2025 | Nucala, Bexsero, Shingrix |
| Verona Pharma, INC. | $189.51 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $164.16 | 2022-2024 | |
| Exact Sciences Corporation | $102.06 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $98.28 | 2021-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $97.10 | 2021-2024 | |
| Insmed, INC. | $93.53 | 2025 | Arikayce, Brinsupri |
| Axsome Therapeutics, INC. | $60.74 | 2025 | Sunosi |
| Idorsia Pharmaceuticals US INC | $54.75 | 2022-2023 | Quviviq |
| Abbott Laboratories | $37.64 | 2022-2023 | Freestyle Libre 2 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35.40 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.33 | 2022 | |
| Mylan Specialty L.P. | $27.86 | 2024 | Yupelri |
| Xeris Pharmaceuticals, INC. | $24.78 | 2023 | Keveyis |
| Biohaven Pharmaceuticals, INC. | $20.79 | 2021 | |
| Viatris Specialty LLC | $20.27 | 2025 | Yupelri |
| Baxter Healthcare | $20.22 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Shield Therapeutics INC | $18.70 | 2024 | |
| Mallinckrodt Hospital Products INC. | $18.61 | 2024 | Terlivaz |
| Phathom Pharmaceuticals, INC. | $17.03 | 2024 | Voquezna |
| Hologic Sales and Service, LLC | $16.12 | 2022 | |
| Insulet Corporation | $15.16 | 2024 | Omnipod |
| Merck Sharp & Dohme LLC | $15.12 | 2021 | |
| Horizon Therapeutics Plc | $13.42 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.